
Vipadenant
CAS No. 442908-10-3
Vipadenant( BIIB-014 | BIIB 014 | BIIB014 )
Catalog No. M14510 CAS No. 442908-10-3
A potent and selective A2A adenosine receptor with Ki of 1.3 nM.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 43 | In Stock |
![]() ![]() |
5MG | 71 | In Stock |
![]() ![]() |
10MG | 110 | In Stock |
![]() ![]() |
25MG | 200 | In Stock |
![]() ![]() |
50MG | 332 | In Stock |
![]() ![]() |
100MG | 494 | In Stock |
![]() ![]() |
500MG | 1071 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameVipadenant
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent and selective A2A adenosine receptor with Ki of 1.3 nM.
-
DescriptionA potent and selective A2A adenosine receptor with Ki of 1.3 nM; displays 50-fold selectivity over A1 and A2B, and no activity against A3, P450 isoforms and hERG; shows excellent preclinical pharmacokinetics, and demonstrates strong oral activity in commonly used models of Parkinson's disease.(In Vivo):Vipadenant (0.3-30 mg/kg) produces a dose-dependent reduction in catalepsy. Vipadenant (10 mg/kg) does not produce any statistically significant dyskinetic episodes in 6-OHDA-lesioned rats during a 19-day dosing regimen. In the mouse and rat haloperidol-induced hypolocomotion models, vipadenant has a minimum effective dose of 0.1 and 1 mg/kg, respectively. Vipadenant (3 and 10 mg/kg, p.o.) is able to increase contralateral rotations in 6-OHDA lesioned rats.
-
In Vitro——
-
In VivoVipadenant (0.3-30 mg/kg) produces a dose-dependent reduction in catalepsy. Vipadenant (10 mg/kg) does not produce any statistically significant dyskinetic episodes in 6-OHDA-lesioned rats during a 19-day dosing regimen. In the mouse and rat haloperidol-induced hypolocomotion models, vipadenant has a minimum effective dose of 0.1 and 1 mg/kg, respectively. Vipadenant (3 and 10 mg/kg, p.o.) is able to increase contralateral rotations in 6-OHDA lesioned rats.
-
SynonymsBIIB-014 | BIIB 014 | BIIB014
-
PathwayApoptosis
-
TargetAdenosine Receptor
-
RecptorA1|A2A|A3
-
Research AreaNeurological Disease
-
Indication——
Chemical Information
-
CAS Number442908-10-3
-
Formula Weight321.3366
-
Molecular FormulaC16H15N7O
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 31 mg/mL
-
SMILESNC1=NC(C2=CC=CO2)=C(N=NN3CC4=CC=C(N)C(C)=C4)C3=N1
-
Chemical Name3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-[(4-amino-3-methylphenyl)methyl]-7-(2-furanyl)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Gillespie RJ, et al. J Med Chem. 2009 Jan 8;52(1):33-47.
2. Pinna A. Expert Opin Investig Drugs. 2009 Nov;18(11):1619-31.
3. Brooks DJ, et al. Clin Neuropharmacol. 2010 Mar-Apr;33(2):55-60.
molnova catalog



related products
-
MRS 1754
MRS 1754 is a selective antagonist radioligand for the A2B adenosine receptor. It has a very low affinity for A1 and A3 receptors of both humans and rats.
-
A2B receptor antagon...
A2B receptor antagonist 2 is an antagonist of adenosine receptor A2B (Ki = 2.30 μM for rA1, 6.8 μM for rA2A, 3.44 μM for hA2B).
-
A2A receptor antagon...
A2A receptor antagonist 1 is an antagonist of both adenosine A2A receptor and A1 receptor with Kis of 4 and 264 nM, respectively.